DXCM vs TNDM
DXCM: Dexcom is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems that help people with diabetes manage their condition with real-time data. TNDM: Tandem Diabetes Care provides advanced, consumer-focused automated insulin delivery systems designed to simplify diabetes management.
Side-by-side fundamentals
| Metric | DXCM | TNDM | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $85.74 | $16.52 | |
| Market cap | $32.4B | $1.1B | |
| P/E as of 2026-10-20 | 33.89 | n/a | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | 0.93 | n/a | |
| Net margin FY2025, SEC XBRL | +17.9% | -20.2% | DXCM higher |
| Gross margin FY2025, SEC XBRL | +60.1% | +53.8% | DXCM higher |
| Operating margin FY2025, SEC XBRL | +19.6% | -18.5% | DXCM higher |
| ROE FY2025, SEC XBRL | +30.5% | -131.9% | DXCM higher |
| ROA FY2025, SEC XBRL | +13.2% | -23.2% | DXCM higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | n/a | 4.62 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +15.6% | +7.9% | DXCM higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | +8.2% | DXCM higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.89 | 1.12 | |
| 1-year return as of 2026-10-20 close | +25.3% | +6.3% | DXCM higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.